Here, we report that trametinib, a specific MEK1/2 inhibitor, is identified by the phenotype-based screening platform ATRIVIEW® to induce neuronal differentiation of adult NSCs from an AD mouse model. Here, MAP2K1 is linked to Alzheimer disease.